By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem webinar discusses industry implications of large-scale MCSGP purification
Bubendorf, Switzerland: – The leading CDMO for peptides and oligonucleotides manufacturing, Bachem is to host a further webinar on its implementation of large-scale purification of synthetic peptides and oligomers using the Multicolumn Counter-current Solvent Gradient Purification (MCSGP) system under cGMP conditions.
Following the success of its earlier webinar ‘Process-scale MCSGP purification of large synthetic molecules’ in early November, Bachem is returning to the subject due to rapidly increasing industry demand for commercial scale processing of oligomers and peptides.
Free online registration
The new webinar ‘Large-scale TIDES purification with MCSGP under GMP’ will be hosted on the US Zoom platform on Tuesday, December 5, 2023, commencing at 17:00 hrs. CET (UTC +1) and lasting for approximately 60 minutes. Registration for the event is free of charge and available online (see Resources).
The presentations and discussion will provide further updates on Bachem’s transition from batch production to continuous large-scale manufacturing of peptides and oligonucleotides.
New industry standard
Bachem has become the first ‘tides manufacturer to introduce MCSGP systems for continuous purification, enabling it to purify faster and very sustainably tens of kilograms of TIDES to GMP standards.
The session will focus on why MCSGP is becoming the new industry standard for ‘tides purification. In a three-way discussion, Bachem’s leading technologist in the chromatography field, Dr. Ralf Eisenhuth, will be joined by two pioneers of MCSGP technology. Prof. Massimo Morbidelli and Thomas Müller-Späth are respectively co-founder and CEO of ChromaCon AG, which recently became part of YMC, Japan.
The session will also feature contributions from the USA from Bachem Business Development Manager Keith Porter, a specialist in the field of solid-phase peptide synthesis (SPPS).
- Ralf Eisenhuth studied organic chemistry at University of Karlsruhe. Since joining Bachem in 2008. he has held increasingly senior positions, ranging from process development to leading the large-scale purification of peptides at Bubendorf. In his current position as Process Manager of Chromatography and Technology Transfer, Dr. Eisenhuth is focusing on innovative purification technologies. He is credited as inventor on several patented processes.
- Keith Porter studied Organic Chemistry and Materials Science at the University of Illinois Urbana Champaign. Keith has more than ten years of research and development experience in the field of solid-phase peptide synthesis (SPPS) and spent most of his career striving to improve this technique. In 2021, he joined Bachem as Business Development Manager. Keith published several scientific articles during his career.
- Massimo Morbidelli is co-founder of ChromaCon AG, a company spin off from his original in biopharmaceutics research on the integrated continuous manufacturing of therapeutic proteins, and its automation and digitalization. He is Professor Emeritus at the ETH Zurich and at the Polytechnic University of Milan and a member of the Italian Academy of Sciences (Accademia dei Lincei), as well as being a recipient of the ERC Advanced Grant on Continuous Digitalized Bioprocesses (CoDiBio). He is co-author of more than 750 papers, 23 international patents, and six books.
- Thomas Müller-Späth is CEO and co-founder of ChromaCon, having collaborated with Professor Morbidelli, as part of the group investigating multi‑column technology for the purification of proteins at the Swiss Federal Institute of Technology (ETH Zurich). He is also credited as inventor on several patents, and author of numerous scientific articles on continuous chromatography for biopharmaceuticals.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
Click on Bachem webinar ‘Large-scale TIDES purification with MCSGP under GMP’ to register for the event.
Click on Bachems News to see latest News & Events.